These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31271708)

  • 1. [The effect of intravitreally administered angiogenesis inhibitor on the concentration of angiotensin-converting enzyme in the blood serum and lacrimal fluid in patients with diabetic macular edema].
    Neroev VV; Chesnokova NB; Okhotsimskaya TD; Ryabina MV; Fadeeva VA; Pavlenko TА; Beznos OV
    Probl Endokrinol (Mosk); 2019 Jun; 65(2):72-78. PubMed ID: 31271708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
    Wood EH; Karth PA; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in Diabetic Macular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital.
    Ku WN; Tien PT; Lin CJ; Chiang CC; Hsia NY; Lai CT; Muo CH; Bair H; Chen HS; Lin JM; Chen WL; Tsai YY
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Impact of antiangiogenic therapy on ocular blood flow and microcirculation in diabetic macular edema].
    Neroev VV; Kiseleva TN; Okhotsimskaya TD; Fadeeva VA; Ramasanova KA
    Vestn Oftalmol; 2018; 134(4):3-10. PubMed ID: 30166504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic functionality and static changes of retinal vessels in diabetic patients treated with intravitreal ranibizumab.
    Benatti L; Corvi F; Tomasso L; Darvizeh F; La Spina C; Querques L; Bandello F; Querques G
    Acta Diabetol; 2017 Jan; 54(1):39-43. PubMed ID: 27600440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.
    Sorour OA; Sabrosa AS; Yasin Alibhai A; Arya M; Ishibazawa A; Witkin AJ; Baumal CR; Duker JS; Waheed NK
    Int Ophthalmol; 2019 Oct; 39(10):2361-2371. PubMed ID: 31119505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA.
    Zhioua I; Semoun O; Lalloum F; Souied EH
    Retina; 2015 Jul; 35(7):1429-35. PubMed ID: 26102440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report.
    Yoshimoto M; Takeda N; Yoshimoto T; Matsumoto S
    J Med Case Rep; 2021 Jul; 15(1):403. PubMed ID: 34311786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema.
    Lim SW; Bandala-Sanchez E; Kolic M; Rogers SL; McAuley AK; Lim LL; Wickremasinghe SS
    Invest Ophthalmol Vis Sci; 2018 Nov; 59(13):5382-5390. PubMed ID: 30452591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison Study of Ranibizumab and Aflibercept in Patients with Naive Diabetic Macular Edema in Presence of Serous Retinal Detachment.
    Kaldırım H; Yazgan S; Kırgız A; Atalay K; Savur F
    Curr Eye Res; 2019 Sep; 44(9):987-993. PubMed ID: 30983426
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
    Okamoto M; Yamashita M; Ogata N
    Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.
    Tetikoğlu M; Yüksel Z; Aktas S; Sağdik HM; Özcura F
    Int Ophthalmol; 2018 Dec; 38(6):2381-2388. PubMed ID: 29030794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
    Campochiaro PA; Khanani A; Singer M; Patel S; Boyer D; Dugel P; Kherani S; Withers B; Gambino L; Peters K; Brigell M;
    Ophthalmology; 2016 Aug; 123(8):1722-1730. PubMed ID: 27236272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.